AgingResearch.NewsJoin free

Chengdu DIAO Pharmaceutical Group

CompanyChina

Chengdu DIAO Pharmaceutical Group develops one asset, in phase 2 (DA-302168S in overweight or obesity). Mostly small molecule acting on GLP1R; based in China.

1
Asset
Furthest stage
Phase 2
0
Trials
1
Signal

Pipeline

1

  • DA-302168S

    Activates GLP-1 receptors to promote weight loss and improve cardiometabolic risk factors.

    Phase 2, Small molecule, GLP1R, overweight or obesity

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals2
  • Similar companies6

Papers

Intelligence